Despite the challenges posed by this variability, our findings support the hypothesis that LDLR, delivered at a time when early histologic and immunologic features of lung inflammation are apparent, increases the likelihood of recovery in a subset of mice (approximately 25%). The gene discussed is LDLR; the disease is inflammatory response.